SH2 and SH3 domains: Potential targets for anti-cancer drug design
- 1 November 1995
- journal article
- review article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 34 (3) , 125-132
- https://doi.org/10.1016/1056-8719(95)00082-7
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- The ins and outs of Raf kinasesTrends in Biochemical Sciences, 1994
- Cyclic Peptide Inhibitors of Phosphatidylinositol 3-Kinase p85 SH2 Domain BindingBiochemical and Biophysical Research Communications, 1994
- Activation of Phosphatidylinositol-3′ Kinase by Src-Family Kinase SH3 Binding to the p85 SubunitScience, 1994
- Biased combinatorial libraries: novel ligands for the SH3 domain of phosphatidylinositol 3-kinaseJournal of the American Chemical Society, 1993
- How receptor tyrosine kinases activate rasTrends in Biochemical Sciences, 1993
- Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signalCell, 1993
- Phosphatidylinositol 3-kinase p85 SH2 domain specificity defined by direct phosphopeptide/SH2 domain bindingBiochemistry, 1993
- SH2 domains recognize specific phosphopeptide sequencesPublished by Elsevier ,1993
- Identification of a Ten-Amino Acid Proline-Rich SH3 Binding SiteScience, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987